Impact of GSTM1, GSTT1 and GSTP1 genes polymorphisms on clinical toxicities and response to concomitant chemoradiotherapy in cervical cancer

References

• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–897.
   PubMed Web of Science ®Google Scholar
• Yuan G, Wu L, Huang M, et al. A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix. Radiat Oncol. 2014;9:1–6.
   PubMed Web of Science ®Google Scholar
• Dunst J, Haensgen G. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy. Strahlenther Onkol. 2001;177:635–640.
   PubMed Web of Science ®Google Scholar
• Strauss HG, Kuhnt T, Laban C, et al. Chemoradiation in cervical cancer with cisplatin and high dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol. 2002;178:378–385.
   PubMed Web of Science ®Google Scholar
• Thomas GM. Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198–1200.
   PubMed Web of Science ®Google Scholar
• Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006;62:35–46.
   PubMed Web of Science ®Google Scholar
• Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Ann Rev Med. 2003;54:437–452.
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J. The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours. Ann Oncol. 2006;17:263–268.
   Web of Science ®Google Scholar
• Qing-Fang L, Ru Y, Kewei L, et al. Genetic polymorphism of GSTP1: prediction of clinical outcome to Oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci. 2010;25:846–852.
   PubMed Web of Science ®Google Scholar
• Mir O, Alexandre J, Tran A, et al. Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol. 2009;20:736–740.
   PubMed Web of Science ®Google Scholar
• Choeyprasert W, Sawangpanich R, Lertsukprasert K, et al. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol. 2013;35:139–143.
   PubMed Web of Science ®Google Scholar
• Sau A, Tregno FP, Valentino F, et al. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys. 2010;500:116–122.
   PubMed Web of Science ®Google Scholar
• Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res. 2006;8:1–7.
   Web of Science ®Google Scholar
• Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54:4313–4320.
   PubMed Web of Science ®Google Scholar
• Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998;34:1493–1499.
   PubMed Web of Science ®Google Scholar
• Yuan ZM, Smith PB, Brundrett RB, et al. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos. 1991;19:625–629.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Saijo N, Tsuchida S. Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem. 1990;265:4296–4301.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;5:1341–1346.
   Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Abbas M, Srivastava K, Imran M, et al. Association of CYP1A1 gene variants rs4646903 (T>C) and rs1048943 (A>G) with cervical cancer in a North Indian population. Eur J Obstet Gynecol Reprod Biol. 2014;176:68–74.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
   PubMed Web of Science ®Google Scholar
• Gauderman W, Morrison J. QUANTO documentation. (Technical report no. 157). Los Angeles, CA:Department of Preventive Medicine, University of Southern California; 2001. Available from http://biostats.usc.edu/Quanto.html
   Google Scholar
• Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer - the Addenbrooke’s experience. Clin Oncol. 2008;20:358–364.
   PubMed Web of Science ®Google Scholar
• Rotman MZ. Chemoirradiation: a new initiative in cancer treatment. 1991 RSNA annual oration in radiation oncology. Radiology. 1992;184:319–327.
   PubMed Web of Science ®Google Scholar
• Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatinum combined with radiation: concepts utilizing projection for new trials and the emergence of carboplatin. Semin Oncol. 1989;16:31–43.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Yang Z, Schumaker LM, et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res. 2003;63:312–318.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851–861.
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2002;94:936–942.
   PubMed Web of Science ®Google Scholar
• Barahmani N, Carpentieri S, Li XN. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro. Oncol. 2009;11:292–300.
   PubMed Web of Science ®Google Scholar
• Zhen S, Hu CM, Bian LH. Glutathione S-Transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis. PLoS One. 2013;8:e83497.
   PubMed Web of Science ®Google Scholar
• Stosic I, Grujicic D, Arsenijevic S, et al. Glutathione S-Transferase T1 and M1 polymorphisms and risk of uterine cervical lesions in women from central Serbia. Asian Pac J Cancer Prev. 2013;15:3201–3205.
   Google Scholar
• Abbas M, Srivastava K, Imran M, et al. Association of Glutathione S-transferase (GSTM1, GSTT1 and GSTP1) polymorphisms and passive smoking in cervical cancer cases from North India. IJBR. 2013;12:655–662.
   Google Scholar
• Welfare M, Monesola AA, Bassendin MF, et al. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomark Prev. 1999;8:289–292.
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Pharmacogenomics and colorectal cancer. Ann Oncol. 2004;15:173–177.
   PubMedGoogle Scholar
• Oldenburg J, Kraggerud SM, Brydøy M, et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and M1, a retrospective cross-sectional study. J Transl Med. 2007;5:1–8.
   PubMed Web of Science ®Google Scholar
• Cabelguenne A, Loriot MA, Stucker I, et al. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer. 2001;93:725–730.
   PubMed Web of Science ®Google Scholar
• McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene. 2006;25:1639–1648.
   PubMed Web of Science ®Google Scholar